Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Electrophilic Modification of PKM2 by 4-Hydroxynonenal and 4-Oxononenal Results in Protein Cross-Linking and Kinase Inhibition.

Camarillo JM, Ullery JC, Rose KL, Marnett LJ.

Chem Res Toxicol. 2017 Feb 20;30(2):635-641. doi: 10.1021/acs.chemrestox.6b00374. Epub 2017 Jan 3.

2.

Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.

Tamada M, Suematsu M, Saya H.

Clin Cancer Res. 2012 Oct 15;18(20):5554-61. doi: 10.1158/1078-0432.CCR-12-0859. Review.

3.

Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth.

Chiavarina B, Whitaker-Menezes D, Martinez-Outschoorn UE, Witkiewicz AK, Birbe R, Howell A, Pestell RG, Smith J, Daniel R, Sotgia F, Lisanti MP.

Cancer Biol Ther. 2011 Dec 15;12(12):1101-13. doi: 10.4161/cbt.12.12.18703. Epub 2011 Dec 15.

4.

Evidence for an alternative glycolytic pathway in rapidly proliferating cells.

Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC.

Science. 2010 Sep 17;329(5998):1492-9. doi: 10.1126/science.1188015.

5.

Identification of small molecule inhibitors of pyruvate kinase M2.

Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC.

Biochem Pharmacol. 2010 Apr 15;79(8):1118-24. doi: 10.1016/j.bcp.2009.12.003. Epub 2009 Dec 11.

6.

M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth.

Cort├ęs-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides JS, Yin H, Muller A, Haberkorn A, Chene P, Sellers WR, Hofmann F.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):489-94. doi: 10.1073/pnas.1212780110. Epub 2012 Dec 24.

7.
8.

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.

Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H.

Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4129-34. doi: 10.1073/pnas.1014769108. Epub 2011 Feb 15.

9.

Molecular association of glucose-6-phosphate isomerase and pyruvate kinase M2 with glyceraldehyde-3-phosphate dehydrogenase in cancer cells.

Das MR, Bag AK, Saha S, Ghosh A, Dey SK, Das P, Mandal C, Ray S, Chakrabarti S, Ray M, Jana SS.

BMC Cancer. 2016 Feb 24;16:152. doi: 10.1186/s12885-016-2172-x.

10.

Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform.

Ning X, Qi H, Li R, Jin Y, McNutt MA, Yin Y.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):126-129. doi: 10.1080/14756366.2017.1404591.

11.

Systems analysis of protein modification and cellular responses induced by electrophile stress.

Jacobs AT, Marnett LJ.

Acc Chem Res. 2010 May 18;43(5):673-83. doi: 10.1021/ar900286y. Review.

12.

Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase.

Mor I, Carlessi R, Ast T, Feinstein E, Kimchi A.

Oncogene. 2012 Feb 9;31(6):683-93. doi: 10.1038/onc.2011.264. Epub 2011 Jul 4.

PMID:
21725354
13.

Pyruvate kinase M2 and cancer: an updated assessment.

Iqbal MA, Gupta V, Gopinath P, Mazurek S, Bamezai RN.

FEBS Lett. 2014 Aug 19;588(16):2685-92. doi: 10.1016/j.febslet.2014.04.011. Epub 2014 Apr 18. Review.

14.

Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.

Chao TK, Huang TS, Liao YP, Huang RL, Su PH, Shen HY, Lai HC, Wang YC.

PLoS One. 2017 Jul 28;12(7):e0182166. doi: 10.1371/journal.pone.0182166. eCollection 2017.

15.

Small ubiquitin-like modifier 1 modification of pyruvate kinase M2 promotes aerobic glycolysis and cell proliferation in A549 human lung cancer cells.

An S, Huang L, Miao P, Shi L, Shen M, Zhao X, Liu J, Huang G.

Onco Targets Ther. 2018 Apr 13;11:2097-2109. doi: 10.2147/OTT.S156918. eCollection 2018.

16.

Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2.

Shankar Babu M, Mahanta S, Lakhter AJ, Hato T, Paul S, Naidu SR.

PLoS One. 2018 Feb 2;13(2):e0191419. doi: 10.1371/journal.pone.0191419. eCollection 2018.

17.

Apigenin Restrains Colon Cancer Cell Proliferation via Targeted Blocking of Pyruvate Kinase M2-Dependent Glycolysis.

Shan S, Shi J, Yang P, Jia B, Wu H, Zhang X, Li Z.

J Agric Food Chem. 2017 Sep 20;65(37):8136-8144. doi: 10.1021/acs.jafc.7b02757. Epub 2017 Sep 11.

PMID:
28829588
18.

HSP40 interacts with pyruvate kinase M2 and regulates glycolysis and cell proliferation in tumor cells.

Huang L, Yu Z, Zhang T, Zhao X, Huang G.

PLoS One. 2014 Mar 21;9(3):e92949. doi: 10.1371/journal.pone.0092949. eCollection 2014.

19.

Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase.

Gao X, Wang H, Yang JJ, Liu X, Liu ZR.

Mol Cell. 2012 Mar 9;45(5):598-609. doi: 10.1016/j.molcel.2012.01.001. Epub 2012 Feb 2.

20.

Supplemental Content

Support Center